CSF findings in patients with anti- @entity3391 receptor- XXXX .

@entity1 @entity198 @entity3391 @entity14752 @entity854
PURPOSE: Anti-NMDAR- @entity198 is a recently described form of @entity14752 . Here, we characterize CSF changes in Chinese patients with anti-NMDAR @entity198 , and explore the relationship between CSF findings and disease outcome. METHODS: The presence of NMDAR antibodies in serum or CSF samples was evaluated in @entity1 diagnosed with @entity198 between October 1, 2010 and August 1, 2014 at the West China Hospital. All @entity1 fulfilling our diagnostic criteria were included and CSF findings were analyzed. @entity1 outcome was assessed after 4, 8, 12, 16, 20, and 24 months using the modified Rankin scale (mRS). RESULTS: Out of 3000 @entity1 with @entity198 screened, 43 patients were anti-NMDAR antibody positive in CSF or serum and included in this study. 62.8% of the @entity1 identified with positive CSFs had positive serum anti-NMDAR samples, while 100% @entity1 with positive serum had positive CSF samples. In the CSF white cell counts were elevated in 58.1% of cases; protein was increased in 18.6%; QAlb>Qlim(Alb) of the blood-CSF barrier was found in 29.3%; intrathecal immunoglobulin synthesis was detected in 17.1%, and 39.5% @entity1 exhibited increased CSF pressures. A longer follow-up period was associated with better outcomes. There was no relationship between changes in CSF findings and outcome. CONCLUSION: The sensitivity of @entity3391 receptor antibody testing is higher in CSF compared to serum. Other @entity854 are present in some patients with Anti-NMDAR- @entity198 , however these changes do not appear to affect prognosis.
